Key result
ACE-inhibition with captopril significantly altered the expression of 1143 genes in metabolic syndrome hearts, counteracting disease-specific pathways and activating cardioprotective mechanisms, compared to only 55 genes in wild-type hearts.
Why the study?
Does ACE-inhibition alter the cardiac transcriptome in a murine metabolic syndrome model?
Does ACE-inhibition alter the cardiac transcriptome in a murine metabolic syndrome model?
ACE-inhibition induces a prominent, model-specific cardioprotective transcriptional response in the metabolic syndrome heart, counteracting several MetS-specific pathological pathways.
Does not yet alter clinical practice; leaves open whether ACE-inhibitor transcriptomic effects translate to human metabolic syndrome hearts.
Cardiovascular disease associated with metabolic syndrome has a high prevalence, but the mechanistic basis of metabolic cardiomyopathy remains poorly understood. We characterised the cardiac transcriptome in a murine metabolic syndrome (MetS) model (LDLR-/-; ob/ob, DKO) relative to the healthy, control heart (C57BL/6, WT) and the transcriptional changes induced by ACE-inhibition in those hearts. RNA-Seq, differential gene expression and transcription factor analysis identified 288 genes differentially expressed between DKO and WT hearts implicating 72 pathways. Hallmarks of metabolic cardiomyopathy were increased activity in integrin-linked kinase signalling, Rho signalling, dendritic cell maturation, production of nitric oxide and reactive oxygen species in macrophages, atherosclerosis, LXR-RXR signalling, cardiac hypertrophy, and acute phase response pathways. ACE-inhibition had a limited effect on gene expression in WT (55 genes, 23 pathways), and a prominent effect in DKO hearts (1143 genes, 104 pathways). In DKO hearts, ACE-I appears to counteract some of the MetS-specific pathways, while also activating cardioprotective mechanisms. We conclude that MetS and control murine hearts have unique transcriptional profiles and exhibit a partially specific transcriptional response to ACE-inhibition.
No takes yet. Share an insight, caveat, or question.
Yakubova et al. (2018) studied Metabolic syndrome cardiomyopathy (n=12). Captopril vs. Physiological saline NaCl 0.9% was evaluated on Differentially expressed genes in the heart transcriptome. ACE-inhibition with captopril significantly altered the expression of 1143 genes in metabolic syndrome hearts, counteracting disease-specific pathways and activating cardioprotective mechanisms, compared to only 55 genes in wild-type hearts.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: